Ligand Pharmaceuticals
LGND
234 hedge funds and large institutions have $1.45B invested in Ligand Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 82 increasing their positions, 73 reducing their positions, and 27 closing their positions.
848% more call options, than puts
Call options by funds: $6.3M | Put options by funds: $665K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
56% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 27
21% more capital invested
Capital invested by funds: $1.21B → $1.45B (+$247M)
12% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 73
5% more funds holding
Funds holding: 222 → 234 (+12)
2.86% more ownership
Funds ownership: 93.2% → 96.05% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$46.7M |
| 2 |
CC
Chicago Capital
Chicago,
Illinois
|
+$22.7M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$20.6M |
| 4 |
FMI
F/M Investments
Washington,
District of Columbia
|
+$10.7M |
| 5 |
PCMF
Private Capital Management (Florida)
Naples,
Florida
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$33.9M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$5.3M |
| 3 |
Man Group
London,
United Kingdom
|
-$5.02M |
| 4 |
Morgan Stanley
New York
|
-$4.58M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$4.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
251
Aigen Investment Management
New York
| – | -$205K | -2,808 | Closed |
|
|
ECM
252
Everence Capital Management
Goshen,
Indiana
| – | -$202 | -2,760 | Closed |
|
|
VI
253
Vestcor Inc
Fredericton,
New Brunswick, Canada
| – | -$95K | -1,293 | Closed |
|
|
SI
254
Stephens Inc
Little Rock,
Arkansas
| – | -$80K | -1,094 | Closed |
|
|
MLICM
255
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$65.6K | -897 | Closed |
|
|
A
256
AlphaQuest
New York
| – | -$19.4K | -266 | Closed |
|
|
SWM
257
Spire Wealth Management
Mclean,
Virginia
| – | -$7.31K | -100 | Closed |
|
|
AWM
258
Avior Wealth Management
Omaha,
Nebraska
| – | -$5.77K | -79 | Closed |
|
259
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$5.78K | -79 | Closed |
|
|
FSWA
260
Financial Synergies Wealth Advisors
Houston,
Texas
| – | -$951 | -13 | Closed |
|
LGND Hedge Fund Activity: Q2 2024 in Review
234 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2024, worth a combined $1.45B — up 21% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new LGND positions and 27 closed out — a net gain of 15 holders — while 82 added to existing stakes and 73 trimmed.
The largest buyer was Congress Asset Management, opening a new position worth an estimated $46.7M. The largest seller was Cardinal Capital Management LLC (Connecticut), cutting an estimated $33.9M.
- 234 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2024, up from 222 in Q1 2024.
- Funds reported $1.45B of Ligand Pharmaceuticals stock for Q2 2024, up 21% quarter-over-quarter.
- 42 funds opened new Ligand Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of +15 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2024 was Congress Asset Management, an estimated $46.7M added.
- The largest Ligand Pharmaceuticals seller in Q2 2024 was Cardinal Capital Management LLC (Connecticut), an estimated $33.9M sold.
Based on aggregated 13F filings for Q2 2024.